Schrödinger, Inc.SDGRNASDAQ
Loading
Schrödinger operates a computational drug discovery platform combining physics-based molecular simulation software with AI/ML to accelerate pharmaceutical R&D. The company generates revenue through software subscriptions (pharmaceutical/biotech clients) and internal drug development collaborations, with a portfolio of clinical-stage assets in oncology and neurology. The stock trades on software revenue stability, pipeline advancement milestones, and partnership deal economics.
Software segment generates recurring subscription revenue with high gross margins (80%+) from computational chemistry tools used in early-stage drug discovery. Drug discovery segment monetizes through upfront payments, research funding, development milestones, and royalties on commercialized products. Competitive advantage lies in proprietary physics-based algorithms (FEP+, WaterMap) that predict molecular binding affinity more accurately than traditional methods, reducing wet-lab experimentation costs. Pricing power depends on demonstrating ROI through faster hit-to-lead optimization and higher clinical success rates.
Software revenue growth rate and customer retention metrics (net dollar retention, new logo wins among top 20 pharma)
Internal pipeline clinical trial readouts (SGR-1505 MALT1 inhibitor, SGR-2921 CDC7 inhibitor) and IND filings
New collaboration announcements with milestone payment structures and royalty terms
Quarterly cash burn rate and runway visibility given negative FCF profile
Competitive positioning updates versus Relay Therapeutics, Recursion Pharmaceuticals in AI-driven drug discovery space
Technology obsolescence risk as generative AI models (AlphaFold3, ESM-3) democratize protein structure prediction, potentially commoditizing aspects of computational drug discovery
Clinical trial failure risk in internal pipeline could eliminate future royalty revenue stream and damage platform credibility
Regulatory pathway uncertainty for AI/ML-designed drug candidates may extend development timelines and increase costs
Large pharma developing in-house computational capabilities (Amgen, Roche AI labs) reducing reliance on external platforms
Well-funded competitors (Relay Therapeutics $400M+ cash, Recursion $200M+ cash) with alternative approaches (Relay's Dynamo platform, Recursion's phenomics) competing for partnerships
Open-source molecular modeling tools and academic platforms eroding pricing power in commodity simulation tasks
Cash burn of $200M annually with current market cap $900M creates urgency for revenue inflection or capital raise within 18-24 months
Dilution risk from potential equity financing if software growth disappoints or pipeline requires additional investment
Collaboration revenue lumpiness creates quarterly volatility and forecasting difficulty
moderate - Software revenue shows resilience as pharma R&D budgets are relatively stable through cycles, but biotech customer segment (30-40% of software base) faces funding pressure during risk-off periods. Drug discovery collaborations can see delayed decision-making during economic uncertainty. Revenue declined 4.2% YoY likely reflecting biotech funding drought in 2024-2025 rather than core platform issues.
High sensitivity through customer funding dynamics. Rising rates compress biotech valuations and reduce venture/IPO funding availability, directly impacting software customer acquisition and retention among emerging biopharma. Company's own cash position ($300M+ estimated) benefits from higher yields on treasury holdings, partially offsetting operational losses. Valuation multiple contracts as risk-free rates rise (currently 3.4x P/S versus historical 8-10x range).
Moderate exposure through customer credit risk. Biotech customers facing funding challenges may delay renewals or negotiate payment terms. Collaboration partners' financial health affects milestone payment reliability. Company maintains strong balance sheet (3.25x current ratio, 0.35x debt/equity) minimizing own financing risk, but customer base credit quality matters for revenue visibility.
growth - Attracts biotech/healthcare growth investors betting on platform adoption inflection and pipeline optionality. Current 54.6% one-year decline reflects risk-off rotation from unprofitable growth names. Requires high risk tolerance given negative margins, cash burn, and binary clinical outcomes. Not suitable for value/income investors given no earnings, no dividends, and elevated valuation on sales basis despite compression.
high - Stock exhibits elevated volatility (beta likely 1.5-2.0x) driven by binary clinical trial events, lumpy collaboration announcements, and quarterly revenue misses. Small market cap ($900M) and negative sentiment amplify price swings. Recent 30.5% three-month decline and 41.1% six-month decline demonstrate downside volatility during risk-off periods.